查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1874254

結核病（TB）診斷：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Tuberculosis (TB) Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球結核病（TB）診斷市場預計在 2024 年達到 30.7 億美元，預計到 2031 年將達到 41.49 億美元，2025 年至 2031 年的複合年成長率為 4.5%。

結核病（TB）是感染疾病，通常由結核分枝桿菌（MTB）引起。結核病主要侵襲肺部，但也可能涉及身體其他部位。大多數感染者沒有症狀，這種狀態稱為潛伏性結核病。約10%的潛伏性性行為感染會發展為活動性結核病，如果不治療，約有一半的感染者會死亡。活動性結核病的典型症狀包括慢性咳嗽伴隨血痰、發燒、盜汗和體重減輕。這種體重減輕正是「肺癆」（consumption）一詞的由來。其他器官的感染也會引起多種症狀。

全球結核病診斷市場的發展動力源自於應對結核病持續高發生率、提高疾病檢測和控制水準的迫切需求，尤其是在高發生率地區。世界衛生組織為實現消除結核病的目標，加大了對結核病控制計畫的投入，並推廣了分子檢測、人工智慧輔助X光篩檢和就地檢驗等先進診斷工具的應用。此外，將結核病篩檢納入全民健康覆蓋（UHC）和綜合呼吸系統疾病防治規劃等更廣泛的醫療保健計劃，也提升了檢測能力。同時，對愛滋病毒感染者、醫護人員、移民和囚犯等高風險族群的篩檢需求，也推動了對快速、準確、分散式診斷的需求，這些診斷方法能夠提供當日檢測結果，並指導治療決策。

儘管結核病診斷技術取得了顯著進步，但市場擴張仍面臨許多障礙。其中一個關鍵挑戰是，中低收入國家取得尖端診斷工具的機會不均，這些國家基礎設施落後，集中檢測系統不完善，無法支援廣泛部署。此外，先進的分子診斷和影像技術成本高昂，尤其是考慮到設備維護、耗材以及醫護人員專業培訓的費用，這仍然是一大障礙。診斷平台分發過程中涉及的監管和物流複雜性，尤其是在偏遠農村地區，也減緩了其普及應用。最後，各國診斷演算法的差異，加上醫療資金的波動和供應鏈體系的薄弱，限制了符合指南的檢測方法的持續實施，並繼續阻礙著大幅降低結核病發病率的努力。

全球主要企業包括丹納赫、羅氏、賽默飛世爾科技、BD 和雅培。前五大廠商約佔33%的市佔率。亞太地區是最大的市場，市佔率超過40%，其次是美洲和歐洲，各佔約40%的市佔率。

本報告旨在按地區/國家、類型和應用對全球結核病 (TB) 診斷市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以收益為準，以2024年為基準年，對結核病（TB）診斷市場規模、估算和預測進行了闡述，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定結核病（TB）診斷業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Danaher
  • Roche
  • Thermo Fisher Scientific
  • BD
  • Abbott
  • Hologic
  • Qiagen
  • BioMerieux
  • Hain Lifescience
  • Oxford Immunotec

按類型分類的細分市場

  • 基於培養的診斷
  • 痰液塗片顯微鏡檢查
  • 快速分子診斷
  • 其他

應用領域

  • 診斷檢查室
  • 醫院

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Tuberculosis (TB) Diagnostics was estimated to be worth US$ 3070 million in 2024 and is forecast to a readjusted size of US$ 4149 million by 2031 with a CAGR of 4.5% during the forecast period 2025-2031.

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

The global TB diagnostics market is being propelled by the urgent need to improve disease detection and control in response to the persistent burden of tuberculosis, particularly in high-prevalence regions. Efforts to reach WHO's End TB goals have elevated funding for TB programs, driving the rollout of advanced diagnostic tools like molecular assays , X-ray based screening solutions with AI assistance, and point-of-care tests. Furthermore, increasing integration of TB screening within broader healthcare initiatives-such as universal healthcare coverage and integrated respiratory disease programs-has expanded testing capacity. The push to screen high-risk populations, including people living with HIV, healthcare workers, migrants, and prison inmates, has also increased demand for rapid, accurate, and decentralized diagnostic methods capable of delivering same-day results and guiding treatment decisions.

Despite significant advancements in TB diagnostics, substantial barriers continue to hinder market expansion. One major challenge is inconsistent access to cutting-edge diagnostic tools in low- and middle-income countries, where infrastructure remains limited and centralized laboratory systems struggle to support widespread deployment. Additionally, the cost of advanced molecular and imaging technologies remains a deterrent, particularly when factoring in expenses for equipment maintenance, consumables, and the specialized training required for healthcare personnel. The regulatory and logistical complexities involved in distributing diagnostic platforms-especially in remote rural areas-also slow down adoption. Finally, the co-existence of disparate diagnostic algorithms across countries, combined with variable healthcare funding and weak supply chain systems, continues to limit consistent implementation of guideline-compliant testing and undermines efforts to significantly reduce TB incidence.

Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%. APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.

This report aims to provide a comprehensive presentation of the global market for Tuberculosis (TB) Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Tuberculosis (TB) Diagnostics by region & country, by Type, and by Application.

The Tuberculosis (TB) Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis (TB) Diagnostics.

Market Segmentation

By Company

  • Danaher
  • Roche
  • Thermo Fisher Scientific
  • BD
  • Abbott
  • Hologic
  • Qiagen
  • BioMerieux
  • Hain Lifescience
  • Oxford Immunotec

Segment by Type

  • Culture-Based Diagnostics
  • Sputum Smear Microscopy
  • Rapid Molecular Diagnostics
  • Others

Segment by Application

  • Diagnostic Laboratories
  • Hospitals

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Tuberculosis (TB) Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Tuberculosis (TB) Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Tuberculosis (TB) Diagnostics Product Introduction
  • 1.2 Global Tuberculosis (TB) Diagnostics Market Size Forecast (2020-2031)
  • 1.3 Tuberculosis (TB) Diagnostics Market Trends & Drivers
    • 1.3.1 Tuberculosis (TB) Diagnostics Industry Trends
    • 1.3.2 Tuberculosis (TB) Diagnostics Market Drivers & Opportunity
    • 1.3.3 Tuberculosis (TB) Diagnostics Market Challenges
    • 1.3.4 Tuberculosis (TB) Diagnostics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Tuberculosis (TB) Diagnostics Players Revenue Ranking (2024)
  • 2.2 Global Tuberculosis (TB) Diagnostics Revenue by Company (2020-2025)
  • 2.3 Key Companies Tuberculosis (TB) Diagnostics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Tuberculosis (TB) Diagnostics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Tuberculosis (TB) Diagnostics
  • 2.6 Tuberculosis (TB) Diagnostics Market Competitive Analysis
    • 2.6.1 Tuberculosis (TB) Diagnostics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Tuberculosis (TB) Diagnostics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis (TB) Diagnostics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Culture-Based Diagnostics
    • 3.1.2 Sputum Smear Microscopy
    • 3.1.3 Rapid Molecular Diagnostics
    • 3.1.4 Others
  • 3.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type
    • 3.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (2020-2031)
    • 3.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Diagnostic Laboratories
    • 4.1.2 Hospitals
  • 4.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application
    • 4.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (2020-2031)
    • 4.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region
    • 5.1.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025)
    • 5.1.3 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031)
    • 5.1.4 Global Tuberculosis (TB) Diagnostics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 5.2.2 North America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 5.3.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 5.5.2 South America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.3.2 United States Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.4.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.5.2 China Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.6.2 Japan Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.7.2 South Korea Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
    • 6.9.2 India Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Danaher
    • 7.1.1 Danaher Profile
    • 7.1.2 Danaher Main Business
    • 7.1.3 Danaher Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.1.4 Danaher Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Danaher Recent Developments
  • 7.2 Roche
    • 7.2.1 Roche Profile
    • 7.2.2 Roche Main Business
    • 7.2.3 Roche Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.2.4 Roche Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Roche Recent Developments
  • 7.3 Thermo Fisher Scientific
    • 7.3.1 Thermo Fisher Scientific Profile
    • 7.3.2 Thermo Fisher Scientific Main Business
    • 7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Thermo Fisher Scientific Recent Developments
  • 7.4 BD
    • 7.4.1 BD Profile
    • 7.4.2 BD Main Business
    • 7.4.3 BD Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.4.4 BD Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 BD Recent Developments
  • 7.5 Abbott
    • 7.5.1 Abbott Profile
    • 7.5.2 Abbott Main Business
    • 7.5.3 Abbott Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.5.4 Abbott Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Abbott Recent Developments
  • 7.6 Hologic
    • 7.6.1 Hologic Profile
    • 7.6.2 Hologic Main Business
    • 7.6.3 Hologic Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.6.4 Hologic Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Hologic Recent Developments
  • 7.7 Qiagen
    • 7.7.1 Qiagen Profile
    • 7.7.2 Qiagen Main Business
    • 7.7.3 Qiagen Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.7.4 Qiagen Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Qiagen Recent Developments
  • 7.8 BioMerieux
    • 7.8.1 BioMerieux Profile
    • 7.8.2 BioMerieux Main Business
    • 7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.8.5 BioMerieux Recent Developments
  • 7.9 Hain Lifescience
    • 7.9.1 Hain Lifescience Profile
    • 7.9.2 Hain Lifescience Main Business
    • 7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Hain Lifescience Recent Developments
  • 7.10 Oxford Immunotec
    • 7.10.1 Oxford Immunotec Profile
    • 7.10.2 Oxford Immunotec Main Business
    • 7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Products, Services and Solutions
    • 7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Oxford Immunotec Recent Developments

8 Industry Chain Analysis

  • 8.1 Tuberculosis (TB) Diagnostics Industrial Chain
  • 8.2 Tuberculosis (TB) Diagnostics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Tuberculosis (TB) Diagnostics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Tuberculosis (TB) Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Tuberculosis (TB) Diagnostics Market Trends
  • Table 2. Tuberculosis (TB) Diagnostics Market Drivers & Opportunity
  • Table 3. Tuberculosis (TB) Diagnostics Market Challenges
  • Table 4. Tuberculosis (TB) Diagnostics Market Restraints
  • Table 5. Global Tuberculosis (TB) Diagnostics Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Tuberculosis (TB) Diagnostics Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Tuberculosis (TB) Diagnostics Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Tuberculosis (TB) Diagnostics
  • Table 10. Global Tuberculosis (TB) Diagnostics Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis (TB) Diagnostics as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Tuberculosis (TB) Diagnostics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Tuberculosis (TB) Diagnostics Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Tuberculosis (TB) Diagnostics Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Tuberculosis (TB) Diagnostics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Tuberculosis (TB) Diagnostics Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Tuberculosis (TB) Diagnostics Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Tuberculosis (TB) Diagnostics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Danaher Basic Information List
  • Table 32. Danaher Description and Business Overview
  • Table 33. Danaher Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Danaher (2020-2025)
  • Table 35. Danaher Recent Developments
  • Table 36. Roche Basic Information List
  • Table 37. Roche Description and Business Overview
  • Table 38. Roche Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Roche (2020-2025)
  • Table 40. Roche Recent Developments
  • Table 41. Thermo Fisher Scientific Basic Information List
  • Table 42. Thermo Fisher Scientific Description and Business Overview
  • Table 43. Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Thermo Fisher Scientific (2020-2025)
  • Table 45. Thermo Fisher Scientific Recent Developments
  • Table 46. BD Basic Information List
  • Table 47. BD Description and Business Overview
  • Table 48. BD Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of BD (2020-2025)
  • Table 50. BD Recent Developments
  • Table 51. Abbott Basic Information List
  • Table 52. Abbott Description and Business Overview
  • Table 53. Abbott Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Abbott (2020-2025)
  • Table 55. Abbott Recent Developments
  • Table 56. Hologic Basic Information List
  • Table 57. Hologic Description and Business Overview
  • Table 58. Hologic Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Hologic (2020-2025)
  • Table 60. Hologic Recent Developments
  • Table 61. Qiagen Basic Information List
  • Table 62. Qiagen Description and Business Overview
  • Table 63. Qiagen Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Qiagen (2020-2025)
  • Table 65. Qiagen Recent Developments
  • Table 66. BioMerieux Basic Information List
  • Table 67. BioMerieux Description and Business Overview
  • Table 68. BioMerieux Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of BioMerieux (2020-2025)
  • Table 70. BioMerieux Recent Developments
  • Table 71. Hain Lifescience Basic Information List
  • Table 72. Hain Lifescience Description and Business Overview
  • Table 73. Hain Lifescience Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Hain Lifescience (2020-2025)
  • Table 75. Hain Lifescience Recent Developments
  • Table 76. Oxford Immunotec Basic Information List
  • Table 77. Oxford Immunotec Description and Business Overview
  • Table 78. Oxford Immunotec Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Tuberculosis (TB) Diagnostics Business of Oxford Immunotec (2020-2025)
  • Table 80. Oxford Immunotec Recent Developments
  • Table 81. Key Raw Materials Lists
  • Table 82. Raw Materials Key Suppliers Lists
  • Table 83. Tuberculosis (TB) Diagnostics Downstream Customers
  • Table 84. Tuberculosis (TB) Diagnostics Distributors List
  • Table 85. Research Programs/Design for This Report
  • Table 86. Key Data Information from Secondary Sources
  • Table 87. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Tuberculosis (TB) Diagnostics Product Picture
  • Figure 2. Global Tuberculosis (TB) Diagnostics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Tuberculosis (TB) Diagnostics Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Tuberculosis (TB) Diagnostics Report Years Considered
  • Figure 5. Global Tuberculosis (TB) Diagnostics Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Tuberculosis (TB) Diagnostics Revenue in 2024
  • Figure 7. Tuberculosis (TB) Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Culture-Based Diagnostics Picture
  • Figure 9. Sputum Smear Microscopy Picture
  • Figure 10. Rapid Molecular Diagnostics Picture
  • Figure 11. Others Picture
  • Figure 12. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Tuberculosis (TB) Diagnostics Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Diagnostic Laboratories
  • Figure 15. Product Picture of Hospitals
  • Figure 16. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Tuberculosis (TB) Diagnostics Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Tuberculosis (TB) Diagnostics Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Tuberculosis (TB) Diagnostics Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value (%), (2020-2031)
  • Figure 29. United States Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Tuberculosis (TB) Diagnostics Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Tuberculosis (TB) Diagnostics Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Tuberculosis (TB) Diagnostics Industrial Chain
  • Figure 51. Tuberculosis (TB) Diagnostics Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed